Acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen-binding domain from Clostridium histolyticum collagenase.
Bottom Line: However, repeated dosing is required for sustained therapeutic effect as the efficacy of bFGF decreases rapidly following its diffusion from bone defect sites.The affinity of the fusion protein towards collagen and demineralized bone matrix (DBM) was also confirmed by collagen-binding assays.Taken together, these properties suggest that the CB-bFGF/collagen composite is a promising material for bone repair in the clinical setting.
Affiliation: Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Kanagawa, Japan.Show MeSH
Related in: MedlinePlus
Mentions: New bone volume and bone mineral content in the femurs of rats locally injected with 0.58 nmol bFGF and CB-bFGF were significantly higher than those in the PBS-injection group [Fig. 2(A–C)]. However, no differences in these parameters were detected between the bFGF and CB-bFGF injection groups.
Affiliation: Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Kanagawa, Japan.